ArticleCureus2025
Searching for Clues in the Diagnosis of McArdle Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction McArdle disease (glycogen storage disorder type 5) is an autosomal recessive metabolic myopathy caused by a myophosphorylase enzyme deficiency. Most patients develop symptoms during childhood; however, diagnosis is usually delayed until adulthood. Our study aimed to identify clues for an earlier recognition of this rare disease. Materials and methods This is a retrospective case series of 15 patients with McArdle syndrome, as diagnosed histologically and/or genetically, who were evaluated at the Cleveland Clinic Neurologic Institute. Data related to demographics, symptoms, exam findings, laboratory test results, genetic testing, muscle biopsy, and prior misdiagnoses were analyzed. Results Fifteen patients with McArdle disease were identified with a median age at symptom onset of 20 years (IQR=11.5-31.25). Symptoms included exertional myalgia and fatigue in all patients (n=15) and the second wind phenomenon in 53% (n=8). Creatine kinase (CK) values were elevated in 930/931 measurements (range 273-75510 IU/L), and myoglobinuria was seen in 60% (n=9). All patients exhibited significant fluctuations in CK, defined as a maximum-to-minimum ratio greater than 5 (ratio range: 5.4-276.6, median ratio: 20.4). Electromyographies (EMGs) were normal in 33% (n=5/15). Median age at diagnosis was 34 years (IQR=28-42). Median delay in diagnosis was 11 years (IQR=5-17). Ten patients (67%) were initially misdiagnosed, and the most common misdiagnosis was autoimmune myositis (n=5, 33%). Conclusions A lack of or underreporting of myoglobinuria or the second wind phenomenon by the patients can lead to a delay in the diagnosis of McArdle disease. Persistently elevated baseline CK without objective weakness and at times dramatically fluctuating CK levels are important diagnostic clues. Physical exam and EMG are often non-diagnostic. Increased awareness of this condition is critical to avoid misdiagnoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.